Potent and conditional redirected T cell killing of tumor cells using Half DVD-Ig-Reference-Cited by-同舟云学术

Potent and conditional redirected T cell killing of tumor cells using Half DVD-Ig

Published:2017-06-05 Issue:1 Volume:9 Page:121-129
ISSN:1674-800X
Container-title:Protein & Cell
language:en
Short-container-title:Protein Cell

Author:

Bardwell Philip D.,Staron Matthew M.,Liu Junjian,Tao Qingfeng,Scesney Susanne,Bukofzer Gail,Rodriguez Luis E.,Choi Chee-Ho,Wang Jennifer,Chang Qing,Dong Feng,Donawho Cherrie,Wang Jieyi,Grinnell Christine M.,Tarcsa Edit,Hutchins Charles,Ghayur Tariq,Gu Jijie

Publisher

Springer Science and Business Media LLC

Subject

Cell Biology,Drug Discovery,Biochemistry,Biotechnology

Link

http://link.springer.com/article/10.1007/s13238-017-0429-z/fulltext.html

Reference29 articles.

1. Baeuerle PA, Reinhardt C (2009) Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res 69:4941–4944

2. Benjamin JE, Stein AS (2016) The role of blinatumomab in patients with relapsed/refractory acute lymphoblastic leukemia. Ther Adv Hematol 7:142–156

3. Chapman AP, Antoniw P, Spitali M, West S, Stephens S, King DJ (1999) Therapeutic antibody fragments with prolonged in vivo half-lives. Nat Biotechnol 17:780–783

4. Chatenoud L, Bluestone JA (2007) CD3-specific antibodies: a portal to the treatment of autoimmunity. Nat Rev Immunol 7:622–632

5. Cheadle EJ (2006) MT-103 Micromet/MedImmune. Curr Opin Mol Ther 8:62–68

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anti‐PD‐1/Her2 Bispecific Antibody IBI315 Enhances the Treatment Effect of Her2‐Positive Gastric Cancer through Gasdermin B‐Cleavage Induced Pyroptosis;Advanced Science;2023-08-16

2. Manufacturability and functionality assessment of different formats of T-cell engaging bispecific antibodies;mAbs;2023-07-04

3. Fc-comprising scDb-based trivalent, bispecific T-cell engagers for selective killing of HER3-expressing cancer cells independent of cytokine release;Journal for ImmunoTherapy of Cancer;2021-11

4. A scDb-based trivalent bispecific antibody for T-cell-mediated killing of HER3-expressing cancer cells;Scientific Reports;2021-07-06

5. Bispecific antibody simultaneously targeting PD1 and HER2 inhibits tumor growth via direct tumor cell killing in combination with PD1/PDL1 blockade and HER2 inhibition;Acta Pharmacologica Sinica;2021-05-14